Last reviewed · How we verify
Ecklonia cava Phlorotannin
Ecklonia cava Phlorotannin has antioxidant and anti-inflammatory properties.
Ecklonia cava Phlorotannin has antioxidant and anti-inflammatory properties. Used for Cardiovascular disease prevention.
At a glance
| Generic name | Ecklonia cava Phlorotannin |
|---|---|
| Also known as | PH100 |
| Sponsor | Bota Bio Co., Ltd. |
| Drug class | Phlorotannin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
It works by scavenging free radicals and inhibiting pro-inflammatory pathways, which may contribute to its therapeutic effects.
Approved indications
- Cardiovascular disease prevention
Common side effects
- Unknown
Key clinical trials
- Phase I Study of PH100 (Ecklonia Cava Phlorotannins) (PHASE1)
- Phase 2a Study to Evaluate the Safety and Efficacy of PH100 Tablet in T2DM Patients With Recent Cardiovascular (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ecklonia cava Phlorotannin CI brief — competitive landscape report
- Ecklonia cava Phlorotannin updates RSS · CI watch RSS
- Bota Bio Co., Ltd. portfolio CI